A new generic alternative for GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) provides payers with the chance to better manage care in chronic obstructive pulmonary disease (COPD), a condition in which high out-of-pocket costs often lead to lower compliance and an increased risk of hospitalization. But payers also are experimenting with innovative care management that they hope will prove to find cost-effective ways to help patients better manage their own conditions.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.